Alkermes (ALKS) Total Current Liabilities (2011 - 2026)
Alkermes (ALKS) posted quarterly Total Current Liabilities of $662.1 million for Q2 2026, up 30.86% year-over-year from $506.0 million in Q2 2025, and up 10.44% quarter-over-quarter from $599.5 million in Q1 2026.
Alkermes (ALKS) Total Current Liabilities (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Total Current Liabilities for 16 consecutive years, with $662.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Current Liabilities rose 30.86% year-over-year to $662.1 million; the TTM figure through Jun 2026 stood at $662.1 million (up 30.86% YoY), while the FY2025 annual figure was $543.4 million, up 16.82% from the prior year.
- Total Current Liabilities advanced to $662.1 million in Q2 2026 per ALKS's latest filing, from $599.5 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $662.1 million in Q2 2026 and bottomed at $438.5 million in Q2 2022.
- Historically, Total Current Liabilities has averaged $499.7 million across 5 years, with a median of $490.0 million in 2023.
- Annual changes were most pronounced in 2024 — Total Current Liabilities slipped 10.58% — and 2026, when it surged 35.1%.
- Alkermes' Total Current Liabilities stood at $497.7 million in 2022, then advanced by 4.52% to $520.2 million in 2023, then slipped by 10.58% to $465.2 million in 2024, then gained by 16.82% to $543.4 million in 2025, then rose by 21.83% to $662.1 million in 2026.
- Business Quant data shows ALKS's Total Current Liabilities at $662.1 million in Q2 2026, $599.5 million in Q1 2026, and $543.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 1.79 Bn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 662.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 662.09 Mn |
| Mar 31, 2026 | 599.50 Mn |
| Dec 31, 2025 | 543.44 Mn |
| Sep 30, 2025 | 474.36 Mn |
| Jun 30, 2025 | 505.96 Mn |
| Mar 31, 2025 | 443.73 Mn |
| Dec 31, 2024 | 465.20 Mn |
| Sep 30, 2024 | 453.71 Mn |
| Jun 30, 2024 | 515.55 Mn |
| Mar 31, 2024 | 458.98 Mn |
| Dec 31, 2023 | 520.22 Mn |
| Sep 30, 2023 | 503.11 Mn |
| Jun 30, 2023 | 487.19 Mn |
| Mar 31, 2023 | 492.91 Mn |
| Dec 31, 2022 | 497.74 Mn |
| Sep 30, 2022 | 469.56 Mn |
| Jun 30, 2022 | 438.52 Mn |
| Mar 31, 2022 | 462.36 Mn |
| Dec 31, 2021 | 471.29 Mn |
| Sep 30, 2021 | 452.98 Mn |